Cerliponase Alfa
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Cerliponase alfa: From CLN2 Disease to Scheie Syndrome
One-Sentence Summary
Cerliponase alfa is a recombinant human tripeptidyl peptidase-1 (TPP1) enzyme replacement therapy delivered by intracerebroventricular infusion, indicated for CLN2 disease (Neuronal Ceroid Lipofuscinosis Type 2 / Batten disease). The TxGNN model predicts it may be effective for Scheie Syndrome as its top-ranked candidate (score 99.98%), with 9 additional rare disease predictions also identified. All 10 predicted indications carry L5 evidence (model prediction only, no clinical trials or supporting publications) and a uniform Hold recommendation due to fundamental mechanistic incompatibilities between TPP1 enzyme replacement and each predicted disease target.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | CLN2 Disease (Neuronal Ceroid Lipofuscinosis Type 2 / Batten Disease) |
| Predicted New Indication | Scheie Syndrome (MPS I-S, top prediction) |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 |
| Taiwan Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why This Prediction Requires Caution
Cerliponase alfa’s mechanism of action data was not available in this evidence pack. Based on established pharmacological knowledge: cerliponase alfa is a recombinant human TPP1 (tripeptidyl peptidase-1), a serine protease that resides in lysosomes and degrades peptide fragments from ceroid lipofuscin. In CLN2 disease, loss-of-function mutations in the CLN2 gene result in TPP1 deficiency, leading to pathological accumulation of ceroid lipofuscin in CNS neurons. Cerliponase alfa compensates for this deficiency by direct intracerebroventricular (ICV) infusion, bypassing the blood-brain barrier to deliver the enzyme to brain lysosomes.
Scheie syndrome (MPS I-S) is caused by a partial deficiency of α-L-iduronidase (IDUA), a completely distinct lysosomal enzyme that degrades dermatan sulfate and heparan sulfate glycosaminoglycans. TPP1 and IDUA share no substrate, no structural homology, and no functional overlap. Furthermore, MPS I-S is a systemic disease requiring body-wide enzyme delivery — cerliponase alfa’s ICV route restricts distribution to CNS tissue and cannot address the visceral, skeletal, or corneal manifestations that characterize MPS I. An approved ERT for MPS I (laronidase / Aldurazyme®) already exists.
The uniformly high TxGNN prediction scores across all 10 predicted indications (ranging from 99.90% to 99.98%) strongly suggest the model is detecting shared “lysosomal storage disease” ontology nodes in the knowledge graph rather than genuine enzyme-substrate relationships. Across every candidate — from Gaucher disease (glucocerebrosidase deficiency) to juvenile myoclonic epilepsy (ion channel disorder) to ichthyosis (skin barrier defect) — the mechanistic analysis reveals no biologically plausible connection to TPP1 replacement therapy. This pattern is consistent with a systematic knowledge graph artifact in the LSD disease cluster.
All Predicted Indications — Mechanistic Assessment
| Rank | Disease | TxGNN Score | Evidence | Decision | Key Mechanistic Concern |
|---|---|---|---|---|---|
| 1 | Scheie syndrome | 99.98% | L5 | Hold | MPS I-S: IDUA deficiency — unrelated enzyme; laronidase already approved |
| 2 | Hurler syndrome | 99.97% | L5 | Hold | MPS I-H: IDUA deficiency (severe form) — same mismatch; laronidase approved |
| 3 | Lysosomal storage disease w/ skeletal involvement | 99.95% | L5 | Hold | Broad LSD category (GAG accumulation); TPP1 has no role in skeletal LSD subtypes |
| 4 | Cholesteryl ester storage disease | 99.93% | L5 | Hold | LAL/LIPA deficiency (lipase); sebelipase alfa already approved |
| 5 | Gaucher disease | 99.93% | L5 | Hold | GBA/GCase deficiency; retrieved publication is natural-history study, not a cerliponase trial |
| 6 | Familial encephalopathy w/ neuroserpin inclusion bodies | 99.93% | L5 | Hold | ER conformational disease (SERPINI1 misfolding) — not lysosomal; cerliponase alfa cannot clear ER aggregates |
| 7 | Wolman disease w/ hypolipoproteinemia & acanthocytosis | 99.92% | L5 | Hold | Complete LAL deficiency; same enzyme family mismatch as CESD |
| 8 | Myoclonic epilepsy, juvenile, susceptibility to | 99.92% | L5 | Hold | Polygenic GABA/ion channel epilepsy; no lysosomal enzyme deficiency; no mechanistic entry point for TPP1 |
| 9 | Proximal myopathy w/ extrapyramidal signs | 99.92% | L5 | Hold | Muscle/extrapyramidal syndrome; ICV route cannot deliver enzyme to skeletal muscle |
| 10 | Autosomal ichthyosis syndrome w/ fatal disease course | 99.90% | L5 | Hold | Skin barrier defect (ABCA12/SNAP29); no lysosomal link; ICV route anatomically unfeasible for skin disease |
Clinical Trial Evidence
Currently no clinical trials are registered for cerliponase alfa in any of the 10 predicted indications.
Literature Evidence
No relevant literature is available for the top predicted indication (Scheie Syndrome).
A single publication was retrieved for the Rank 5 prediction (Gaucher disease):
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 41527340 | 2026 | Natural History / Observational | Journal of Inherited Metabolic Disease | Natural history mapping framework using Gaucher disease as a precision medicine model for LSD drug development — not a cerliponase alfa intervention study |
Important: This publication does not evaluate cerliponase alfa for Gaucher disease. It examines Gaucher disease natural history as a methodological model for rare disease research. Its retrieval reflects lysosomal storage disorder keyword overlap, not direct drug-disease relevance.
Taiwan Market Information
Cerliponase alfa is not currently authorized in Taiwan (0 licenses registered).
For reference: Cerliponase alfa (brand name Brineura®) is approved by the FDA (2017) and EMA for the treatment of CLN2 disease (Batten disease) in children aged ≥3 years. Taiwan registration status should be verified via the TFDA drug database.
Safety Considerations
Please refer to the SmPC (Brineura® product monograph) for safety information. No drug-drug interaction data was identified in this evidence review, and TFDA label warnings and contraindications have not yet been retrieved (see Data Gaps below).
Conclusion and Next Steps
Decision: Hold (All 10 Predicted Indications)
Rationale: All ten TxGNN-predicted indications show fundamental mechanistic mismatches with cerliponase alfa’s pharmacology: the drug replaces TPP1 serine protease specifically for CLN2 disease, while every predicted target involves a distinct lysosomal enzyme (IDUA, GBA, LAL), a non-lysosomal pathological mechanism (ER conformational disease, ion channelopathy), or an anatomically inaccessible tissue (skin, skeletal muscle) for ICV-delivered therapy. The uniformly high prediction scores across mechanistically unrelated diseases are a strong signal of a knowledge graph artifact — LSD ontology clustering — rather than genuine repurposing potential.
To proceed, the following is needed:
- Resolve Data Gap DG001: Download and parse the Brineura® SmPC (TFDA or EMA) to complete safety pre-screening
- Resolve Data Gap DG002: Retrieve full MOA documentation from DrugBank (DB13173) to formally document TPP1 enzyme class and substrate specificity
- KG artifact investigation: Review TxGNN knowledge graph to determine whether “lysosomal storage disease” as a disease category node is causing systematic false-positive enzyme replacement therapy predictions — individual enzyme-substrate relationships (IDUA, GBA, GAA, LAL, TPP1) should be encoded as distinct nodes
- No additional clinical evidence collection is recommended for these 10 indications until the KG artifact question is resolved
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.